Search
Caribou Biosciences Inc
CRBUAdd to Watchlist
1.475USD
+0.015+1.03%
Market hours （ET）Quotes delayed by 15 min
143.00MMarket Cap
LossP/E TTM
More Details of Caribou Biosciences Inc Company
Caribou Biosciences, Inc. is a clinical-stage clustered regularly interspaced short palindromic repeats (CRISPR) genome-editing biopharmaceutical company engaged in developing transformative therapies for patients with devastating diseases. The Company’s genome-editing platform, including its Cas12a chRDNA technology, enables superior precision to develop cell therapies that are armored to potentially improve activity against disease. Caribou is advancing a pipeline of off-the-shelf cell therapies from its CAR-T platform to offer broad access and rapid availability of treatments for patients with hematologic malignancies and autoimmune diseases. Its genome-editing platform, including its novel chRDNA technology, enables more precise genome editing of allogeneic cell therapies. It is advancing its pipeline of allogeneic CAR-T cell therapies with clinical development programs targeting the treatment of hematologic malignancies and autoimmune diseases.
Caribou Biosciences Inc Info
Ticker SymbolCRBU
Company nameCaribou Biosciences Inc
IPO dateJul 23, 2021
CEOHaurwitz (Rachel E)
Number of employees147
Security typeOrdinary Share
Fiscal year-endJul 23
Address2929 7Th Street, Ste 120
CityBERKELEY
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code94710
Phone15109826030
Websitehttps://www.cariboubio.com/
Ticker SymbolCRBU
IPO dateJul 23, 2021
CEOHaurwitz (Rachel E)
Company Executives of Caribou Biosciences Inc
Name
Name/Position
Position
Shareholding
Change
Ms. Barbara G. McClung, J.D.
Ms. Barbara G. McClung, J.D.
Chief Legal Officer, Corporate Secretary
Chief Legal Officer, Corporate Secretary
391.94K
-6.98%
Mr. Sriram (Sri) Ryali
Mr. Sriram (Sri) Ryali
Chief Financial Officer
Chief Financial Officer
17.36K
-316.82%
Dr. Rachel E. Haurwitz, Ph.D.
Dr. Rachel E. Haurwitz, Ph.D.
President, Chief Executive Officer, Co-Founder, Director
President, Chief Executive Officer, Co-Founder, Director
--
--
Dr. Nancy C. Whiting, Pharm.D.
Dr. Nancy C. Whiting, Pharm.D.
Independent Director
Independent Director
--
--
Ms. Ran Zheng
Ms. Ran Zheng
Independent Director
Independent Director
--
--
Dr. Dara Richardson-Heron, M.D.
Dr. Dara Richardson-Heron, M.D.
Independent Director
Independent Director
--
--
Ms. Ruhi A. Khan
Ms. Ruhi A. Khan
Chief Business Officer
Chief Business Officer
--
--
Dr. Scott N. Braunstein, M.D.
Dr. Scott N. Braunstein, M.D.
Independent Director
Independent Director
--
--
Mr. Andrew L. Guggenhime
Mr. Andrew L. Guggenhime
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. Natalie R. Sacks, M.D.
Dr. Natalie R. Sacks, M.D.
Independent Director
Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Ms. Barbara G. McClung, J.D.
Ms. Barbara G. McClung, J.D.
Chief Legal Officer, Corporate Secretary
Chief Legal Officer, Corporate Secretary
391.94K
-6.98%
Mr. Sriram (Sri) Ryali
Mr. Sriram (Sri) Ryali
Chief Financial Officer
Chief Financial Officer
17.36K
-316.82%
Dr. Rachel E. Haurwitz, Ph.D.
Dr. Rachel E. Haurwitz, Ph.D.
President, Chief Executive Officer, Co-Founder, Director
President, Chief Executive Officer, Co-Founder, Director
--
--
Dr. Nancy C. Whiting, Pharm.D.
Dr. Nancy C. Whiting, Pharm.D.
Independent Director
Independent Director
--
--
Ms. Ran Zheng
Ms. Ran Zheng
Independent Director
Independent Director
--
--
Dr. Dara Richardson-Heron, M.D.
Dr. Dara Richardson-Heron, M.D.
Independent Director
Independent Director
--
--
FAQs
Who are the top five shareholders of Caribou Biosciences Inc?
The top five shareholders of Caribou Biosciences Inc are: Ms. Barbara G. McClung, J.D.
How many institutions hold shares of Caribou Biosciences Inc (CRBU)?
As of 2026Q1, 337 institutions hold shares of Caribou Biosciences Inc, with a combined market value of approximately 35.96M, accounting for 36.25% of the total shares. Compared to 2025Q4, institutional shareholding has increased by -24026667.00.